Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 5.18 1.37% 0.07
MRSN closed up 1.37 percent on Monday, December 10, 2018, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical MRSN trend table...

Date Alert Name Type % Chg
Dec 10 New 52 Week Low Weakness 0.00%
Dec 10 Wide Bands Range Expansion 0.00%
Dec 10 Oversold Stochastic Weakness 0.00%
Dec 7 New 52 Week Closing Low Bearish 1.37%
Dec 7 1,2,3 Retracement Bearish Bearish Swing Setup 1.37%
Dec 7 180 Bearish Setup Bearish Swing Setup 1.37%
Dec 7 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.37%
Dec 7 Outside Day Range Expansion 1.37%
Dec 7 Wide Bands Range Expansion 1.37%
Dec 7 Oversold Stochastic Weakness 1.37%

Older signals for MRSN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Is MRSN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.96
52 Week Low 4.96
Average Volume 92,001
200-Day Moving Average 13.4772
50-Day Moving Average 6.9484
20-Day Moving Average 5.6415
10-Day Moving Average 5.395
Average True Range 0.5524
ADX 47.25
+DI 7.7582
-DI 22.5257
Chandelier Exit (Long, 3 ATRs ) 5.2628
Chandelier Exit (Short, 3 ATRs ) 6.6172
Upper Bollinger Band 6.5336
Lower Bollinger Band 4.7494
Percent B (%b) 0.24
BandWidth 31.626341
MACD Line -0.5498
MACD Signal Line -0.6122
MACD Histogram 0.0624
Fundamentals Value
Market Cap 117.65 Million
Num Shares 22.7 Million
EPS -16.23
Price-to-Earnings (P/E) Ratio -0.32
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.68
Resistance 3 (R3) 5.66 5.47 5.59
Resistance 2 (R2) 5.47 5.35 5.48 5.56
Resistance 1 (R1) 5.33 5.27 5.40 5.35 5.54
Pivot Point 5.14 5.14 5.18 5.15 5.14
Support 1 (S1) 5.00 5.02 5.07 5.02 4.82
Support 2 (S2) 4.81 4.94 4.82 4.80
Support 3 (S3) 4.67 4.81 4.77
Support 4 (S4) 4.69